Tam, C. S. L., Kahl, B. S., Munir, T., Robak, T., Ghia, P., Opat, S., Walker, P., Lasica, M., Flinn, I. W., Jurczak, W., Shen, J., Lefebure, M., Hirata, J. H., Shadman, M. (2026). Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7046